[HTML][HTML] Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis

M Seretny, GL Currie, ES Sena, S Ramnarine, R Grant… - Pain®, 2014 - Elsevier
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting
from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose …

Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings

EY Ibrahim, BE Ehrlich - Critical reviews in oncology/hematology, 2020 - Elsevier
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy
that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by …

[HTML][HTML] Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment

J Burgess, M Ferdousi, D Gosal, C Boon… - Oncology and …, 2021 - Springer
Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review

SH Chu, YJ Lee, ES Lee, Y Geng, XS Wang… - Supportive Care in …, 2015 - Springer
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer
patients who undergo chemotherapy with platinum analogues, taxanes, vinca alkaloids …

[HTML][HTML] Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal …

A Molassiotis, HL Cheng, V Lopez, JSK Au, A Chan… - BMC cancer, 2019 - Springer
Background There are inconsistencies in the literature regarding the prevalence and
assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored …

[HTML][HTML] Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

K Sałat - Pharmacological Reports, 2020 - Springer
Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

[PDF][PDF] Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations

S Hou, B Huh, HK Kim, KH Kim, S Abdi - Pain Physician, 2018 - painphysicianjournal.com
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a commonly
encountered disease entity following chemotherapy for cancer treatment. Although only …

Updates in the treatment of chemotherapy-induced peripheral neuropathy

JN Mezzanotte, M Grimm, NV Shinde, T Nolan… - … treatment options in …, 2022 - Springer
Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common
toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and …

Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data

JS Gewandter, AS Kleckner, JH Marshall… - Supportive Care in …, 2020 - Springer
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling complication
of many chemotherapies. We investigated the feasibility of using health plan claims and …

Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update

CL Loprinzi, C Lacchetti, J Bleeker… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To update the ASCO guideline on the recommended prevention and treatment
approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in …